Strategic Move Enhances Oncology Innovation for Both Human and Animal Treatments
Vivos Inc. (OTCQB: RDGL) is gearing up for significant advancements with its recent Reg A-1 filing, representing a strategic move aiming to bolster its human trials and expand its animal therapies, marking a notable step forward for the company.
Vivos Inc Stock Price Today | OTC RDGL Live Ticker – Investing.com
Vivos Inc. is at the forefront of Precision Radionuclide Therapy™ (PRnT™), a cutting-edge approach to treating cancers in both humans and animals. This proprietary technology promises effective and targeted cancer treatment options, enhancing the company’s position in the oncology field.
For an in-depth exploration of Vivos Inc.’s groundbreaking advancements with RadioGel™ and IsoPet®, including recent FDA designations, executive leadership updates, and detailed share structure information, please refer to our previous articles. Vivos Inc. Innovation in Precision Radionuclide Therapy ‣ TradersQue covers the comprehensive developments that have positioned Vivos Inc. at the cutting edge of medical and veterinary oncology innovation. Vivos Inc. Announces IDE Submission for RadioGel™ (tradersque.com)
Strategic Financial Move to Boost Market Presence and Growth Potential
The Reg A-1 filing VIVOS INC (Form: 1-A, Received: 06/28/2024 16:06:24) (otcmarkets.com) represents an audited, Tier 2 offering, which can expedite Vivos Inc.’s qualification to uplist to a national securities exchange like NYSE or NASDAQ. This move reflects the company’s strong growth potential and commitment to advancing its market presence. The maximum gross proceeds from the sale of the shares of Vivos Inc.’s common stock being offered is $9,000,000. Assuming the maximum number of shares is sold, the company estimates net proceeds of approximately $8,900,000 after estimated offering expenses.
Allocation of Funds
Funding Human Trials at Mayo Clinic
Vivos Inc.’s Reg A-1 filing will provide essential funding for the RadioGel™ human trials at Mayo Clinic, subject to FDA approval of the IDE and Mayo Clinic IRB authorization. These trials will specifically target papillary thyroid cancer across different stages and among various tumor sizes. The IDE submission for these trials has been confirmed, setting the stage for potential breakthroughs in oncological therapies.
Expanding IsoPet® Animal Therapies
In addition to human trials, Vivos Inc. plans to expand its IsoPet® animal therapies business by launching in new U.S. market regions more IsoPet® veterinary clinics offering PRnT cancer treatment to canine, feline, and equine patients. Vivos Inc. plans to allocate the remaining funds to support the launch of new regional centers, conduct polymer development tests to refine production processes, comply with FDA ‘Good Manufacturing Practices’ (GMP) standards, improve product yield, and streamline the product delivery timeline.
Additional Expenses
The company will also maintain its focus on safeguarding intellectual property by increasing the number of approved claims on existing patent applications and finalizing filings related to particle production in both domestic and international markets.
Funding may additionally cover the following:
- Offering expenses
- Corporate and public company costs
- Research and development
- Application development
- General working capital (approximately 10% of the proceeds)
Until these funds are utilized, the net proceeds will be invested in short-term, investment-grade, interest-bearing securities: including money market accounts, certificates of deposit, commercial paper, and U.S. government-guaranteed obligations. The precise allocation of funds and timing of expenditures will vary based on numerous factors. Vivos Inc. reserves the right to adjust the use of proceeds as necessary. No additional financing plans are currently contemplated, notably dilution, pending any unsold shares.
The Road Ahead
With visionary leadership, premium product development, a solid share structure, and an attractive share price, Vivos Inc. is poised for continued success in the fields of human and animal oncology. The Reg A-1 filing is a pivotal step that supports both clinical trials and market expansion, enabling the company to advance its innovative RadioGel™ and IsoPet® therapies. This move underscores Vivos Inc.’s commitment to pioneering cancer treatment solutions and driving significant growth in the market.
About Vivos Inc.
Vivos Inc. has developed an Yttrium-90-based injectable Precision Radionuclide Therapy™ medical device to treat tumors in animals (IsoPet®) and humans (RadioGel®). Using the company’s proprietary hydrogel technology, PRnT™ uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. This allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers.
RadioGel® Technology
RadioGel® is a hydrogel liquid containing yttrium-90 phosphate microparticles, administered directly into a tumor. After injection, it gels within the tumor interstitial spaces to keep the radiation sources in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area, minimizing adverse effects on normal organs and tissues. The short half-life of RadioGel® ensures that more than 90% of its therapeutic radiation is delivered within 10 days, allowing for outpatient procedures without risk to family members.
IsoPet® for Veterinary Use
IsoPet® uses the same technology as RadioGel® for treating animals. It has been tested successfully on feline sarcoma at Washington State University and on canine soft tissue sarcomas at the University of Missouri. The FDA has classified IsoPet® as a medical device and does not require pre-market approval for veterinary use, allowing for revenue generation through sales to university hospitals and private clinics.
Vivos Inc. | RadioGel™ | IsoPet® – (OTCMKTS: RDGL)
Meet the Visionaries Behind Vivos Inc.
Meet the innovative minds driving Vivos Inc. forward in the fight against cancer. Our dedicated team combines expertise, passion, and cutting-edge technology to revolutionize cancer treatment. Learn more about our leaders and their groundbreaking work by visiting Meet The Team | RadioGel™
Disclaimer: This article includes paid promotions. We may receive compensation for promoting certain securities. This could influence our content. Please perform your own due diligence and consult with a financial advisor before making any investment decisions.
